Age (years), mean ± SD |
72 ± 9 |
Height (cm), mean ± SD |
171 ± 9 |
Weight (kg), mean ± SD |
77 ± 16 |
BSA (m²), mean ± SD |
1.9 ± 0.2 |
Sex |
|
Male, n (%) |
34 (74%) |
Female, n (%) |
12 (26%) |
Race |
|
White, n (%) |
44 (96%) |
COPD, n (%) |
2 (4%) |
Creatinine (µmol/L), mean ± SD |
130 ± 59 |
eGFR (mL/min), mean ± SD |
53 ± 20 |
NT-proBNP (ng/L), mean ± SD |
3447 ± 3148 |
Heart rate (bpm), mean ± SD |
74 ± 13 |
Cardiovascular history |
|
Atrial fibrillation |
38 (83%) |
NYHA class 3-4 |
46 (100%) |
Hypertension |
32 (70%) |
Coronary artery disease |
33 (72%) |
MR mechanism |
|
Primary, n (%) |
4 (9%) |
Secondary/functional, n (%) |
42 (91%) |
Medications |
|
ACE inhibitors, n (%) |
30 (65%) |
Beta-blockers, n (%) |
34 (74%) |
Digoxin, n (%) |
5 (11%) |
Diuretics, n (%) |
41 (89%) |
MRA, n (%) |
26 (57%) |
ARNI, n (%) |
1 (2%) |
CRT, n (%) |
7 (15%) |
Function |
|
STS-PROM, mean ± SD |
11 ± 8 |
6MWT, mean ± SD |
284 ± 138 |